[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements.) This section presents the unaudited condensed consolidated financial statements for the three and six months ended April 30, 2021, and 2020, detailing financial position, operational results, and cash flows [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) The balance sheet as of April 30, 2021, reflects a substantial strengthening of the company's financial position, driven by significant increases in cash, investments, and equity from recent capital raises | Financial Metric | April 30, 2021 (Unaudited) | October 31, 2020 | | :--- | :--- | :--- | | **Cash and cash equivalents** | $27,703,435 | $6,417,061 | | **Total current assets** | $38,471,948 | $9,368,624 | | **Total assets** | $38,497,522 | $9,452,964 | | **Total current liabilities** | $1,442,871 | $1,188,591 | | **Total shareholders' equity** | $37,613,758 | $8,761,356 | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported no revenue for the three months ended April 30, 2021, but recognized $512,500 in six-month revenue from a licensing agreement, with net loss and loss per share improving year-over-year | Metric | Three Months Ended April 30, 2021 | Three Months Ended April 30, 2020 | | :--- | :--- | :--- | | **Revenue** | $ - | $ - | | **Loss from operations** | $(2,437,282) | $(2,670,137) | | **Net loss attributable to common shareholders** | $(2,398,851) | $(2,640,093) | | **Net loss per share (Basic and diluted)** | $(0.08) | $(0.12) | | Metric | Six Months Ended April 30, 2021 | Six Months Ended April 30, 2020 | | :--- | :--- | :--- | | **Revenue** | $512,500 | $ - | | **Loss from operations** | $(4,670,413) | $(5,300,006) | | **Net loss attributable to common shareholders** | $(4,607,142) | $(5,232,636) | | **Net loss per share (Basic and diluted)** | $(0.17) | $(0.25) | [Condensed Consolidated Statements of Shareholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Shareholders'%20Equity) Shareholders' equity significantly increased to $37.1 million by April 30, 2021, primarily driven by approximately $31.1 million in net proceeds from public and at-the-market offerings - Completed a public offering in March 2021, selling **4,285,715 shares** and raising net proceeds of approximately **$20.3 million**[10](index=10&type=chunk)[13](index=13&type=chunk)[42](index=42&type=chunk) - Raised net proceeds of approximately **$10.8 million** from an at-the-market (ATM) offering during the six months ended April 30, 2021[14](index=14&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended April 30, 2021, cash used in operating and investing activities was significantly offset by $31.4 million provided by financing activities, resulting in a net increase of $21.3 million in cash and cash equivalents | Cash Flow Activity (Six Months Ended April 30) | 2021 | 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | $(2,411,946) | $(3,470,654) | | **Net cash used in investing activities** | $(7,723,853) | $(285,791) | | **Net cash provided by financing activities** | $31,422,173 | $3,153,017 | | **Net increase (decrease) in cash** | $21,286,374 | $(603,428) | | **Cash and cash equivalents at end of period** | $27,703,435 | $2,888,197 | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail the company's primary focus on developing oncology and infectious disease therapies and vaccines, outlining collaborations, clinical trial progress, financing activities, and segment-level financial data - The company's primary operations involve developing therapies and vaccines for oncology (CAR-T for ovarian cancer, vaccines for breast and ovarian cancer) and infectious diseases (COVID-19 therapeutics)[19](index=19&type=chunk) - An Investigational New Drug (IND) application for the CAR-T ovarian cancer therapy was submitted to the FDA in March 2021; the company is addressing an FDA information request and anticipates beginning clinical trials in **Q4 2021**[21](index=21&type=chunk) - Received FDA authorization in December 2020 to begin a Phase 1a clinical trial for a breast cancer vaccine, with the first patient expected to be treated in **July 2021**[26](index=26&type=chunk) - The company manages five reportable segments: CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics, Cancer Diagnostics, and Patent Licensing; for the six months ended April 30, 2021, CAR-T Therapeutics incurred the highest operating costs excluding non-cash compensation (**$1.49 million**)[94](index=94&type=chunk)[95](index=95&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses financial results, noting decreased R&D expenses due to program suspension, $513,000 in licensing revenue, and confirming sufficient liquidity for the next twelve months due to recent financing activities - For the six months ended April 30, 2021, the company recorded revenue of approximately **$513,000** from one license agreement[106](index=106&type=chunk) - Research and development expenses for the six months ended April 30, 2021 decreased by approximately **$869,000** compared to the prior year, primarily due to the suspension of the cancer diagnostics program[110](index=110&type=chunk) - The company believes its existing cash, cash equivalents, and short-term investments are sufficient to fund activities for at least the next twelve months, supported by approximately **$31.1 million** in net proceeds from a public offering and an at-the-market program in H1 2021[116](index=116&type=chunk) - Management identifies Revenue Recognition and Stock-Based Compensation as its most critical accounting policies, which require significant judgments and estimates[120](index=120&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) The company's market risk is limited to interest rate risk on its short-term, fixed-rate, and highly liquid investments, which could affect future returns upon reinvestment - The company's investments consist of short-term, fixed-rate, and highly liquid instruments, which are subject to interest rate risk that could affect returns upon reinvestment[128](index=128&type=chunk) [Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures.) Management concluded that disclosure controls and procedures were effective as of April 30, 2021, with no material changes to internal control over financial reporting during the quarter - Management concluded that disclosure controls and procedures are effective as of the end of the reporting period[129](index=129&type=chunk) - No material changes were made to the company's internal control over financial reporting during the second quarter of fiscal year 2021[129](index=129&type=chunk) [PART II. OTHER INFORMATION](index=30&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings.) The company is not involved in any litigation or other legal proceedings that would have a material adverse effect on its financial condition or results of operations - The company is not involved in any material litigation or legal proceedings[131](index=131&type=chunk) [Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors.) There have been no material changes to the company's risk factors from those disclosed in its Annual Report on Form 10-K for the fiscal year ended October 31, 2020 - No material changes in risk factors have occurred since the fiscal year 2020 Form 10-K filing[132](index=132&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=30&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) The company reported no unregistered sales of equity securities during the period - None[132](index=132&type=chunk) [Exhibits](index=30&type=section&id=Item%206.%20Exhibits.) This section lists the exhibits filed with the Form 10-Q, including an assignment agreement, an amendment to a collaboration agreement, and CEO/CFO certifications - Filed exhibits include an Assignment Agreement with OntoChem GmbH and MolGenie GmbH, and CEO/CFO certifications pursuant to the Sarbanes-Oxley Act[133](index=133&type=chunk) [Signatures](index=31&type=section&id=SIGNATURES) - The report was signed on **June 10, 2021**, by **Dr. Amit Kumar**, Chairman, President and CEO, and **Michael J. Catelani**, COO and CFO[135](index=135&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2020 Commission file number 001-37492 ANIXA BIOSCIENCES, INC. | --- | --- | |----------------------------------------------------------------------------|----------------------------------------------| | (Exact name of registrant as \nDelaware | specified in its charter) \n11-2622630 | | (State or oth ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2020 Commission file number 0-11254 | --- | --- | --- | |------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|-----------------------------------------------------| | Delaware ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2020 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | --- | --- | |-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. | --- | --- | --- | |-------------------------------------------------|--------------------------------------------------------|-----------------------------| | | (Exact name of registrant as specified in its charter) | | | Delaware (State or ...

PART I. FINANCIAL INFORMATION [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements.) This section presents the unaudited condensed consolidated financial statements for the quarterly period ended April 30, 2019, including balance sheets, statements of operations, shareholders' equity, cash flows, and notes, showing increased assets and a widening net loss [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of April 30, 2019, total assets increased to **$7.77 million** from **$6.45 million** at October 31, 2018, driven by higher cash, investments, and receivables, while total liabilities rose to **$1.60 million** and total equity increased to **$6.17 million** Condensed Consolidated Balance Sheet Highlights (Unaudited) | Metric | April 30, 2019 | October 31, 2018 | | :--- | :--- | :--- | | **Total Current Assets** | $7,493,532 | $5,538,372 | | **Total Assets** | $7,765,426 | $6,448,542 | | **Total Current Liabilities** | $1,595,761 | $1,265,111 | | **Total Shareholders' Equity** | $6,543,052 | $5,434,808 | | **Total Liabilities and Equity** | $7,765,426 | $6,448,542 | [Condensed Consolidated Statements of Operations](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) The company reported a net loss attributable to common shareholders of **$7.42 million** for the six months ended April 30, 2019, significantly higher than the **$3.22 million** loss in the prior-year period, primarily due to increased operating costs and a patent impairment charge Six Months Ended April 30, (Unaudited) | Metric | 2019 | 2018 | | :--- | :--- | :--- | | Revenue | $250,000 | $750,000 | | Total Operating Costs and Expenses | $7,826,962 | $4,025,540 | | Loss from Operations | ($7,576,962) | ($3,275,540) | | Net Loss Attributable to Common Shareholders | ($7,419,533) | ($3,216,606) | | Net Loss Per Share (Basic and Diluted) | ($0.38) | ($0.19) | Three Months Ended April 30, (Unaudited) | Metric | 2019 | 2018 | | :--- | :--- | :--- | | Revenue | $250,000 | $750,000 | | Total Operating Costs and Expenses | $2,843,234 | $2,150,954 | | Loss from Operations | ($2,593,234) | ($1,400,954) | | Net Loss Attributable to Common Shareholders | ($2,537,692) | ($1,378,534) | | Net Loss Per Share (Basic and Diluted) | ($0.13) | ($0.08) | [Condensed Consolidated Statement of Shareholders' Equity](index=8&type=section&id=Condensed%20Consolidated%20Statement%20of%20Shareholders'%20Equity) For the six months ended April 30, 2019, total shareholders' equity increased to **$6.54 million** from **$5.43 million**, driven by **$4.36 million** in net proceeds from an at-the-market stock offering and over **$4.0 million** in non-cash stock-based compensation, partially offset by a net loss of **$7.42 million** - Key changes in shareholders' equity for the six months ended April 30, 2019 include a net loss of **$7.42 million**, stock compensation of over **$4.0 million**, and proceeds from an at-the-market offering of **$4.36 million**[8](index=8&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=11&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) For the six months ended April 30, 2019, net cash used in operating activities was **$2.76 million**, investing activities used **$0.93 million**, and financing activities provided **$4.46 million**, resulting in a net increase in cash and cash equivalents of **$0.77 million**, ending the period at **$3.82 million** Cash Flow Summary for the Six Months Ended April 30, (Unaudited) | Cash Flow Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net Cash Used in Operating Activities | ($2,764,290) | ($2,082,481) | | Net Cash (Used in) Provided by Investing Activities | ($925,457) | $2,238,187 | | Net Cash Provided by Financing Activities | $4,456,163 | $677,370 | | **Net Increase in Cash and Cash Equivalents** | **$766,416** | **$833,076** | [Notes to Condensed Consolidated Financial Statements](index=12&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements%20(Unaudited)) The notes detail the company's primary operations in cancer therapeutics (CER-T technology) and diagnostics (Cchek™ platform), covering funding, accounting policies, stock-based compensation, segment information, and a pending shareholder derivative lawsuit - The company's primary focus is on developing its CER-T technology for ovarian cancer and its AI-driven Cchek™ liquid biopsy platform for early cancer detection[12](index=12&type=chunk) - Management believes existing cash and expected cash flows are sufficient to fund activities for the next twelve months, supported by an at-the-market equity offering that raised approximately **$4.36 million** in the period[14](index=14&type=chunk) Net Loss by Segment (Six Months Ended April 30) | Segment | 2019 | 2018 | | :--- | :--- | :--- | | Cancer Diagnostics | ($3,052,355) | ($1,362,451) | | Cancer Therapeutics | ($3,517,219) | ($1,551,067) | | Patent licensing | ($971,969) | ($344,470) | | **Total** | **($7,541,543)** | **($3,257,988)** | [Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&A)](index=27&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations.) Management discusses financial results, highlighting decreased revenue from legacy patent licensing and a significant increase in operating expenses due to intensified R&D and higher non-cash stock-based compensation, while confirming sufficient liquidity for the next 12 months [Results of Operations](index=27&type=section&id=RESULTS%20OF%20OPERATIONS) For the six months ended April 30, 2019, revenue decreased to **$0.25 million** from **$0.75 million** in the prior year, while research and development expenses surged by **$2.08 million** to **$3.52 million**, and general and administrative expenses rose by **$1.45 million** to **$3.35 million**, both primarily due to increased stock compensation, alongside a **$0.42 million** patent asset impairment charge - Revenue for the six months ended April 30, 2019, was **$0.25 million** from a single license agreement, down from **$0.75 million** in the same period of 2018[63](index=63&type=chunk) - Research and development expenses increased by approximately **$2.08 million** for the six-month period, mainly due to a **$1.25 million** increase in stock award compensation and a **$0.82 million** increase in stock option compensation[67](index=67&type=chunk) - General and administrative expenses increased by approximately **$1.45 million** for the six-month period, principally due to a **$0.75 million** increase in stock option compensation and a **$0.70 million** increase in stock award compensation[68](index=68&type=chunk) [Liquidity and Capital Resources](index=30&type=section&id=LIQUIDITY%20AND%20CAPITAL%20RESOURCES) The company's liquidity position is considered sufficient for the next twelve months, with cash, cash equivalents, and short-term investments totaling approximately **$6.57 million** as of April 30, 2019, bolstered by **$4.36 million** raised through an at-the-market equity offering - The company believes its existing cash, cash equivalents, and short-term investments are sufficient to fund activities for the next twelve months[79](index=79&type=chunk) - During the six months ended April 30, 2019, the company raised approximately **$4.36 million** through its at-the-market equity offering of 1,061,032 shares of common stock[79](index=79&type=chunk) - Cash, cash equivalents, and short-term investments increased by approximately **$1.52 million** to **$6.57 million** at April 30, 2019, from **$5.06 million** at the end of fiscal year 2018[79](index=79&type=chunk) [Critical Accounting Policies](index=32&type=section&id=CRITICAL%20ACCOUNTING%20POLICIES) The company identifies Revenue Recognition and Stock-Based Compensation as its most critical accounting policies, requiring significant judgment in recognizing one-time license fees upon agreement execution and valuing stock-based compensation using fair value models with subjective assumptions - Revenue from one-time, paid-up license fees is recognized upon the execution of the agreement, as the company has no further performance obligations[82](index=82&type=chunk) - Stock-based compensation cost is measured at the grant date using fair value models like Black-Scholes or Monte Carlo Simulation, which require significant assumptions regarding expected term, volatility, and risk-free rates[84](index=84&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=34&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk.) The company's exposure to market risk is limited, primarily related to interest rate changes affecting returns on its short-term, fixed-rate investments upon reinvestment - The company's market risk is primarily related to interest rate changes affecting returns on its short-term, fixed-rate investments at the time of reinvestment[88](index=88&type=chunk) [Controls and Procedures](index=34&type=section&id=Item%204.%20Controls%20and%20Procedures.) Based on management's evaluation, including the CEO and CFO, the company's disclosure controls and procedures were effective as of April 30, 2019, with no material changes in internal control over financial reporting during the quarter - Management concluded that the company's disclosure controls and procedures are effective as of April 30, 2019[89](index=89&type=chunk) PART II. OTHER INFORMATION [Legal Proceedings](index=35&type=section&id=Item%201.%20Legal%20Proceedings.) The company is named as a nominal defendant in a putative shareholder derivative complaint filed in November 2018, alleging breach of fiduciary duty by certain current and former officers and directors, with defense costs funded by the company, and potential losses currently inestimable - A shareholder derivative complaint was filed against certain officers and directors, with the company named as a nominal defendant, and the company is indemnifying the individuals and cannot estimate potential losses at this time[90](index=90&type=chunk) [Risk Factors](index=35&type=section&id=Item%201A.%20Risk%20Factors.) There have been no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K for the fiscal year ended October 31, 2018 - No material changes in risk factors were reported since the last Annual Report on Form 10-K[91](index=91&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=35&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds.) None - The company reported no unregistered sales of equity securities during the period[91](index=91&type=chunk) [Exhibits](index=35&type=section&id=Item%206.%20Exhibits.) This section lists the exhibits filed with the Form 10-Q, including certifications by the Chief Executive Officer and Chief Financial Officer as required by the Sarbanes-Oxley Act of 2002 - The report includes required CEO and CFO certifications pursuant to Section 302 and Section 1350 of the Sarbanes-Oxley Act[91](index=91&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q quarterly report pursuant to section 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2019 Commission file number 0-11254 ANIXA BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 11-2622630 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 3150 Almaden Expressway, Suite 250 San Jose, CA 95118 (Address o ...